PANTHERx Rare Pharmacy announced that it was selected by Rhythm Pharmaceuticals (RYTM) as the exclusive U.S. Pharmacy distribution partner for the expanded indication of IMCIVREE for adults and children 4 years of age and older living with acquired hypothalamic obesity. “This new indication for IMCIVREE marks an important scientific milestone for individuals and families affected by acquired hypothalamic obesity, a highly complex disease with historically limited therapeutic options,” said Bansi Nagji, CEO of PANTHERx Rare. “We’re honored to deepen our collaboration with Rhythm Pharmaceuticals, and to help patients receive the personalized, high-touch clinical support necessary to navigate treatment.” PANTHERx has been the exclusive pharmacy distribution partner for IMCIVREE for chronic weight management in adult and pediatric patients 2 years of age and older with obesity due to Bardet-Biedl Syndrome and proopiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency confirmed by genetic testing since 2020.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Wins FDA Nod for Hypothalamic Obesity Therapy
- Rhythm Pharmaceuticals price target raised to $149 from $139 at BofA
- Palatin’s Case Strengthens as Rhythm’s FDA Approval Validates Hypothalamic Obesity Market (PTN)
- Rhythm Pharmaceuticals price target raised to $142 from $131 at Citi
- Rhythm Pharmaceuticals price target raised to $155 from $152 at Citizens